The company said conversations with clinicians at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans covered improved outcomes and easier follow-up visits. The Irvine, California-based company said outcomes demonstrated how iLet supports diabetes care in everyday practice.
iLet, Beta Bionics’ flagship AID system, allows users to “go bionic,” requiring no carb counting or insulin correction calculations. Then, iLet determines 100% of the insulin doses throughout the day. The only input required to get started is the user’s weight. Beta Bionics also has the Mint patch pump under development with a launch expected next year.
The company recently announced the public availability of near-real-time, real-world iLet Bionic Pancreas data through its online dashboard as well, highlighting the relevance of the findings shared at ADA 2026.
Post-market surveillance data covered the real-world population from the first three years of iLet usage. It spanned from May 19, 2023, to May 19, 2026. The analysis evaluating iLet usage among users who had baseline HbA1c and/or time in range data available and uploaded at least two weeks’ worth of CGM data to Beta Bionics.
Beta Bionics said time in range improved by 25%. Dr. Bantwal Baliga serves as director, East Alabama Endocrinology. Baliga said that, prior to iLet, only 20% of his patient population had an A1c under 7.5%. On iLet, 73% achieved GMI ≤7.5%.
Dr. Aaron King of MedFirst Primary Care, Baptist Medical Network, said iLet patient follow-up also represents “the easiest part” of his patient visit. He said they have no settings to adjust and can focus on patient coaching.
“The iLet can be effectively used in primary care to bridge the gap in endocrine care shortages across the U.S.,” said King.
